Factors associated with permanent pacemaker implantation after tricuspid valve surgery
This study aimed to identify the risk factors associated with permanent pacemaker (PPM) implantation following tricuspid valve (TV) surgery.
This study aimed to identify the risk factors associated with permanent pacemaker (PPM) implantation following tricuspid valve (TV) surgery.
This retrospective study investigated the prognostic implications of tricuspid regurgitation (TR) in a cohort of 2679 patients who underwent surgical aortic valve replacement (AVR), specifically assessing the potential benefit of concomitant tricuspid valve intervention in those with moderate TR.
This observational study explores the association between mitral regurgitation (MR) severity and both cardiovascular and all-cause mortality.
A meta-analysis of four randomized controlled trials (RCTs) comparing early aortic valve replacement (either surgical or transcatheter) with a conservative strategy of close clinical surveillance in patients with asymptomatic severe aortic stenosis.
This multicenter observational study evaluates the impact of percutaneous edge-to-edge tricuspid valve repair on overall survival in patients with tricuspid regurgitation across different disease stages.
Meta-analysis of the longest available follow-up outcomes from the six main randomized trials comparing TAVI and SAVR in low surgical risk patients in terms of survival and stroke.
The Cardiac Surgery team at the Cleveland Clinic (Cleveland, Ohio, USA) reviewed multivalve reoperations (involving more than one valve) performed from 2008 to 2022 and identified the determinants of operative mortality in these procedures.
A retrospective observational study evaluating patients who underwent TAVI to identify predictive factors for atrioventricular block (AVB) within 24 hours to 30 days post procedure and to develop a risk stratification tool.
Dr. Juan Diego Sánchez’s perspective on the current state of the art in tricuspid regurgitation treatment.
This study provides increasingly necessary information to optimize decision-making in a population traditionally underrepresented in TAVI clinical trials: nonagenarian patients.